. 2019 Mar 6;4(2):e000460. doi: 10.1136/esmoopen-2018-000460
© Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ on behalf of the European Society for Medical Oncology.
This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and any changes made are indicated. See: http://creativecommons.org/licenses/by/4.0/.
Figure 2.
Level of routine use of biosimilars by prescribers in clinical practice to treat patients.